5-amino-1-(3-methoxyphenyl)-3-phenyl-1H-pyrazole | 890764-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-amino-1-(3-methoxyphenyl)-3-phenyl-1H-pyrazole
• 英文别名: 1-(3-methoxyphenyl)-3-phenyl-1H-pyrazol-5-amine；2-(3-methoxyphenyl)-5-phenylpyrazol-3-amine
• CAS: 890764-19-9
• 化学式: C₁₆H₁₅N₃O
• 分子量: 265.315
• InChiKey: QMFCKDVBHWZLDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-amino-1-(3-methoxyphenyl)-3-phenyl-1H-pyrazole 、 苯甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以23%的产率得到N-[2-(3-Methoxy-phenyl)-5-phenyl-2H-pyrazol-3-yl]-benzamide
  参考文献：
  名称：

  Substituent Effects of N-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides on Positive Allosteric Modulation of the Metabotropic Glutamate-5 Receptor in Rat Cortical Astrocytes

  摘要：

  CDPPB [3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide] was recently described as the first centrally active, positive allosteric modulator of rat and human metabotropic glutamate receptor (mGluR) mGluR(5) subtype. We explored the structural requirements for potentiation of glutamate-induced calcium release in naturally expressed mGluR5 in cultured rat astrocytes and increasing affinity for the allosteric antagonist binding site by evaluating 50 analogues of CDPPB. In the fluorometric calcium assay, CDPPB exhibited an EC50 value of 77 +/- 15 nM in potentiating mGluR(5)-mediated responses in cortical astrocytes and a K-i value of 3760 ( 430 nM in displacing [H-3] methoxyPEPy binding in membranes of cultured HEK-293 cells expressing rat mGluR5. The structure-activity relationships showed that electronegative aromatic substituents in the para-position of the benzamide moiety of CDPPB increase potency. Both binding and functional activities were further increased with a halogen atom in the ortho-position of the 1-phenyl ring. These effects of substitution do not match those of either aromatic ring of MPEP [2-methyl-6-(phenylethynyl)-pyridine] for the antagonist allosteric binding site. Combination of the optimal substituents and aromatic positions resulted in 4-nitro-N-(1-(2-fluorophenyl)-3-phenyl-1H-pyrazol-5-yl) benzamide (VU-1545) showing K-i) 156 (29 nM and EC50) 9.6 (1.9 nM in the binding and functional assays, respectively.

  DOI：

  10.1021/jm051252j
• 作为产物：
  描述：

  苯甲腈 在 盐酸 、 potassium tert-butylate 作用下， 以 苯 为溶剂， 反应 24.33h， 生成 5-amino-1-(3-methoxyphenyl)-3-phenyl-1H-pyrazole
  参考文献：
  名称：

  Substituent Effects of N-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides on Positive Allosteric Modulation of the Metabotropic Glutamate-5 Receptor in Rat Cortical Astrocytes

  摘要：

  CDPPB [3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide] was recently described as the first centrally active, positive allosteric modulator of rat and human metabotropic glutamate receptor (mGluR) mGluR(5) subtype. We explored the structural requirements for potentiation of glutamate-induced calcium release in naturally expressed mGluR5 in cultured rat astrocytes and increasing affinity for the allosteric antagonist binding site by evaluating 50 analogues of CDPPB. In the fluorometric calcium assay, CDPPB exhibited an EC50 value of 77 +/- 15 nM in potentiating mGluR(5)-mediated responses in cortical astrocytes and a K-i value of 3760 ( 430 nM in displacing [H-3] methoxyPEPy binding in membranes of cultured HEK-293 cells expressing rat mGluR5. The structure-activity relationships showed that electronegative aromatic substituents in the para-position of the benzamide moiety of CDPPB increase potency. Both binding and functional activities were further increased with a halogen atom in the ortho-position of the 1-phenyl ring. These effects of substitution do not match those of either aromatic ring of MPEP [2-methyl-6-(phenylethynyl)-pyridine] for the antagonist allosteric binding site. Combination of the optimal substituents and aromatic positions resulted in 4-nitro-N-(1-(2-fluorophenyl)-3-phenyl-1H-pyrazol-5-yl) benzamide (VU-1545) showing K-i) 156 (29 nM and EC50) 9.6 (1.9 nM in the binding and functional assays, respectively.

  DOI：

  10.1021/jm051252j

文献信息

• Anti-inflammatory medicaments
  申请人：Flynn L. Daniel

  公开号：US20070191336A1

  公开（公告）日：2007-08-16

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.

  提供了治疗炎症状况的新化合物和使用这些化合物的方法。在一个优选实施例中，调节p38激酶蛋白的激活状态包括将激酶蛋白与新的化合物接触的步骤。
• ANTI-INFLAMMATORY MEDICAMENTS
  申请人：Flynn Daniel L.

  公开号：US20090312349A1

  公开（公告）日：2009-12-17

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

  本发明提供了新型化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在一个优选实施例中，调节p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的活化状态包括将该激酶蛋白与新型化合物接触的步骤。
• Tandem Oxidative Reaction of 1,3-Diarylpropenes and 5-Aminopyrazoles
  作者：Dongping Cheng、Jing-Hua Li、Xiaoliang Xu、Huafang Gu、Hongshuang Xia、Yawei Wang

  DOI：10.1055/a-2145-5916

  日期：2023.12

  The reaction of 5-aminopyrazoles with 1,3-diarylpropenes mediated by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, with subsequent intramolecular cyclization and dehydroaromatization in the presence of Cu(OTf)2/tert-butyl hydroperoxide, gave a series of pyrazolo[3,4-b]pyridines in moderate to excellent yields. The reaction has the advantages of high atom economy, a wide substrate scope, and a one-pot procedure.

  摘要在 2,3-二氯-5,6-二氰基-1,4-苯醌介导下，5-氨基吡唑与 1,3-二芳基丙烯发生反应，随后在 Cu(OTf)2/ 叔丁基过氧化氢存在下发生分子内环化和脱氢芳香化反应，得到一系列吡唑并[3,4-b]吡啶，收率中等到极好。该反应具有原子经济性高、底物范围广和一锅反应等优点。
• EP1836173A4
  申请人：——

  公开号：EP1836173A4

  公开（公告）日：2009-07-08
• [EN] ANTI-INFLAMMATORY MEDICAMENTS<br/>[FR] MEDICAMENTS ANTI-INFLAMMATOIRES
  申请人：DECIPHERA PHARMACEUTICALS LLC

  公开号：WO2006081034A2

  公开（公告）日：2006-08-03

  [EN] Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. ][n a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.
  [FR] Cette invention concerne de nouveaux composés et des procédés d'utilisation de ces composés dans le traitement des états inflammatoires, des maladies hyperprolifératives, des cancers et des maladies se caractérisant par une hypervascularisation. Dans un mode de réalisation préféré, la modulation de l'état d'activation de la protéine kinase p38, de la protéine kinase abl, de la protéine kinase bcr-abl, de la protéine kinase braf, de la protéine kinase VEGFR ou de la protéine kinase, PDGFR consiste à mettre en contact cette protéine kinase avec ces nouveaux composés.